XTX Topco Ltd Invests $788,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

XTX Topco Ltd bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 7,386 shares of the specialty pharmaceutical company’s stock, valued at approximately $788,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JAZZ. Janney Montgomery Scott LLC boosted its position in Jazz Pharmaceuticals by 48.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 10,949 shares of the specialty pharmaceutical company’s stock valued at $1,347,000 after purchasing an additional 3,591 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $380,000. UBS Group AG grew its position in Jazz Pharmaceuticals by 18.4% during the fourth quarter. UBS Group AG now owns 172,947 shares of the specialty pharmaceutical company’s stock valued at $21,272,000 after purchasing an additional 26,844 shares in the last quarter. Coldstream Capital Management Inc. purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $227,000. Finally, Assetmark Inc. grew its position in Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 119 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, Piper Sandler dropped their target price on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ:JAZZ opened at $110.76 on Monday. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.38. The company’s 50-day moving average price is $110.79 and its two-hundred day moving average price is $111.00. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The firm has a market cap of $6.98 billion, a P/E ratio of 22.84, a P/E/G ratio of 1.31 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. As a group, research analysts forecast that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insider Activity

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.